These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 9232612)

  • 41. Recombinant human granulocyte-macrophage colony-stimulating factor in septic neutropenic pediatric cancer patients: detection of circulating hematopoietic precursor cells correlates with rapid granulocyte recovery.
    Fink FM; Maurer-Dengg K; Fritsch G; Mann G; Zoubek A; Falk M; Gadner H
    Med Pediatr Oncol; 1995 Nov; 25(5):365-71. PubMed ID: 7545780
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
    Shaffer DW; Smith LS; Burris HA; Clark GM; Eckardt JR; Fields SM; Weiss GR; Rinaldi DA; Bowen KJ; Kuhn JG
    Cancer Res; 1993 Dec; 53(24):5929-33. PubMed ID: 8261405
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
    Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
    J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.
    Vellenga E; Uyl-de Groot CA; de Wit R; Keizer HJ; Löwenberg B; ten Haaft MA; de Witte TJ; Verhagen CA; Stoter GJ; Rutten FF; Mulder NH; Smid WM; de Vries EG
    J Clin Oncol; 1996 Feb; 14(2):619-27. PubMed ID: 8636779
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
    Liang DC
    Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized clinical trial of granulocyte macrophage colony stimulating factor mouthwash for oral mucositis in head and neck cancer.
    Dodd MJ; Cho MH; Cooper BA; MacPhail L; Miaskowski C
    Eur J Oncol Nurs; 2022 Feb; 56():102093. PubMed ID: 35026498
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Topical curcumin for the prevention of oral mucositis in pediatric patients: case series.
    Elad S; Meidan I; Sellam G; Simaan S; Zeevi I; Waldman E; Weintraub M; Revel-Vilk S
    Altern Ther Health Med; 2013; 19(3):21-4. PubMed ID: 23709456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.
    Herrmann F; Schulz G; Wieser M; Kolbe K; Nicolay U; Noack M; Lindemann A; Mertelsmann R
    Am J Med; 1990 Jun; 88(6):619-24. PubMed ID: 2189305
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines.
    Logan RM; Al-Azri AR; Bossi P; Stringer AM; Joy JK; Soga Y; Ranna V; Vaddi A; Raber-Durlacher JE; Lalla RV; Cheng KKF; Elad S;
    Support Care Cancer; 2020 May; 28(5):2485-2498. PubMed ID: 32080767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis.
    Katano M; Nakamura M; Matsuo T; Iyama A; Hisatsugu T
    Surg Today; 1995; 25(3):202-6. PubMed ID: 7543781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
    Janik JE; Miller LL; Korn EL; Stevens D; Curti BD; Smith JW; Sznol M; Conlon KC; Sharfman W; Urba WJ; Gause BL; Longo DL
    Blood; 2001 Apr; 97(7):1942-6. PubMed ID: 11264156
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of granulocyte-macrophage colony-stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemo-radiotherapy.
    Rosso M; Blasi G; Gherlone E; Rosso R
    J Chemother; 1997 Oct; 9(5):382-5. PubMed ID: 9373795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intestinal permeability in patients with chemotherapy-induced stomatitis.
    Melichar B; Kohout P; Brátová M; Solichová D; Králícková P; Zadák Z
    J Cancer Res Clin Oncol; 2001 May; 127(5):314-8. PubMed ID: 11355146
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer.
    McAleese JJ; Bishop KM; A'Hern R; Henk JM
    Br J Radiol; 2006 Jul; 79(943):608-13. PubMed ID: 16823067
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of recombinant human granulocyte/macrophage-colony-stimulating factor (rHu GM-CSF) and rHu G-CSF administration on neutrophil chemiluminescence assay in patients following cyclic chemotherapy.
    Aslan M; Yucel G; Bozcuk H; Savas B
    Cancer Immunol Immunother; 1998 Nov; 47(3):176-81. PubMed ID: 9829843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Current approaches in prevention and therapy of chemo- and radiotherapy-induced oral mucositis].
    Rosenthal C; Karthaus M
    Wien Med Wochenschr; 2001; 151(3-4):53-65. PubMed ID: 11789420
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis.
    Wang L; Huang XE; Ji ZQ; Liu MY; Qian T; Li L
    Asian Pac J Cancer Prev; 2016; 17(1):413-8. PubMed ID: 26838248
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
    Dinçol D; Samur M; Pamir A; Sencan O; Akbulut H; Yalçin B; Onur H; Demirkazik A; Senler FC; Içli F
    Cancer; 2000 May; 88(9):2033-6. PubMed ID: 10813713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.